FDA on EC access
This article was originally published in The Tan Sheet
Executive Summary
FDA "has never made" the statement that wider access to Plan B could lead to increased promiscuity in women under the age of 16, the agency states in recent letters to members of the House Pro-Choice Caucus. In October, 62 members of the caucus wrote to FDA stating that the agency cited the concern in its May 2004 "not approvable" letter to Barr regarding the firm's switch application. "You attribute to FDA a concern that the agency has never expressed about the proposed Plan B switch to OTC status and we would like to correct the record on this matter at this time," FDA states in a response sent to each signatory of the October letter. The May 6, 2004 memo from CDER Acting Director Steven Galson explaining his decision to find Plan B not approvable notes a lack of studies submitted by the sponsor to address "important potential behavioral changes," including "increased medically risky sexual behavior"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.